{
    "ticker": "OCGN",
    "name": "Ocugen, Inc.",
    "description": "Ocugen, Inc. is a biopharmaceutical company focused on developing transformative gene therapies to treat ocular diseases and other therapeutic areas. Founded in 2013 and headquartered in Malvern, Pennsylvania, Ocugen is committed to addressing unmet medical needs through innovative approaches that harness the power of gene therapy and regenerative medicine. The company is best known for its leading product candidate, OCU300, which is aimed at treating retinal diseases, as well as its collaboration with Bharat Biotech to co-develop and commercialize the COVID-19 vaccine candidate, COVAXIN, for the U.S. market. Ocugen leverages its proprietary modifier gene therapy platform to potentially treat various eye diseases, including retinitis pigmentosa and age-related macular degeneration. With a strong pipeline of candidates in both preclinical and clinical stages, Ocugen is dedicated to advancing its innovative therapies and improving the quality of life for patients suffering from debilitating conditions. The company\u2019s mission is to create a future where everyone has access to effective treatments for ocular diseases and to provide hope to patients through groundbreaking research and development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Malvern, Pennsylvania, USA",
    "founded": "2013",
    "website": "https://www.ocugen.com",
    "ceo": "Shankar Musunuri",
    "social_media": {
        "twitter": "https://twitter.com/OcugenInc",
        "linkedin": "https://www.linkedin.com/company/ocugen/"
    },
    "investor_relations": "https://investors.ocugen.com",
    "key_executives": [
        {
            "name": "Shankar Musunuri",
            "position": "CEO"
        },
        {
            "name": "Mohan S. Iyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "OCU300",
                "OCU410"
            ]
        },
        {
            "category": "COVID-19 Vaccine",
            "products": [
                "COVAXIN"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ocugen, Inc. | Innovative Gene Therapies for Ocular Diseases",
        "meta_description": "Ocugen, Inc. is at the forefront of developing transformative gene therapies for ocular diseases and other therapeutic areas. Discover our innovative products and commitment to patient care.",
        "keywords": [
            "Ocugen",
            "Gene Therapy",
            "Ocular Diseases",
            "Biopharmaceuticals",
            "COVAXIN",
            "OCU300"
        ]
    },
    "faq": [
        {
            "question": "What is Ocugen known for?",
            "answer": "Ocugen is known for its innovative gene therapies and its collaboration with Bharat Biotech on the COVID-19 vaccine candidate, COVAXIN."
        },
        {
            "question": "Who is the CEO of Ocugen?",
            "answer": "Shankar Musunuri is the CEO of Ocugen, Inc."
        },
        {
            "question": "Where is Ocugen headquartered?",
            "answer": "Ocugen is headquartered in Malvern, Pennsylvania, USA."
        },
        {
            "question": "What are Ocugen's main products?",
            "answer": "Ocugen's main products include OCU300, OCU410, and the COVID-19 vaccine COVAXIN."
        },
        {
            "question": "When was Ocugen founded?",
            "answer": "Ocugen was founded in 2013."
        }
    ],
    "competitors": [
        "MRNA",
        "PFE",
        "JNJ",
        "NVAX"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}